Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

37.39 -1.55 (-3.98%)
Streaming Delayed Price Updated: 12:00 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 678,240
Open 38.57
Bid (Size) 37.37 (1)
Ask (Size) 37.42 (2)
Prev. Close 38.94
Today's Range 36.92 - 38.57
52wk Range 19.83 - 94.45
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
APLS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
WHY: NEW YORK, NY - (NewMediaWire) - October 2, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
APLS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal

Performance

YTD
-25.64%
-25.64%
1 Month
-13.25%
-13.25%
3 Month
-57.64%
-57.64%
6 Month
-52.09%
-52.09%
1 Year
-38.75%
-38.75%

More News

Read More
NASDAQ:APLS Shareholder Alert: Deadline on October 2, 2023 Coming Up in Lawsuit Against Apellis Pharmaceuticals, Inc.
Via SBWire
Topics Lawsuit
Exposures Financial Legal
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Why Shares of Apellis Pharmaceuticals Were Down Wednesday
Via The Motley Fool
APLS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
APELLIS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS
From Kahn Swick & Foti, LLC
Via Business Wire
APELLIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
APLS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)
From The Law Offices of Frank R. Cruz
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS
From The Rosen Law Firm PA
Via GlobeNewswire
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Apellis, Party City, and Hayward and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTX, Eos, and Apellis and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.